backgroundaim
angiotensinconvert
enzym
product
angiotensin
receptor
ma
may
moder
advers
effect
angiotensin
ii
liver
diseas
examin
express
novel
compon
renin
angiotensin
system
ra
product
vasoact
effect
angiotensin
bile
duct
ligat
bdl
rat
method
bdl
shamoper
rat
sacrif
week
tissu
blood
collect
gene
express
enzym
activ
peptid
measur
situ
perfus
liver
use
assess
angiotensin
peptid
product
effect
portal
resist
result
hepat
gene
activ
p
plasma
angiotensin
p
ma
receptor
express
p
increas
follow
bdl
compar
sham
perfus
experi
confirm
bdl
liver
produc
increas
angiotensin
p
angiotensin
ii
augment
p
ace
inhibit
whilst
angiotensin
ii
increas
vasoconstrict
cirrhot
liver
angiotensin
effect
portal
resist
conclus
ra
activ
chronic
liver
injuri
associ
upregul
ma
hepat
convers
angiotensin
ii
angiotensin
lead
increas
circul
angiotensin
result
support
presenc
ma
axi
liver
injuri
may
counteract
effect
angiotensin
ii
renin
angiotensin
system
ra
effector
molecul
angiotensin
ii
recognis
play
major
role
tissu
injuri
fibrosi
number
diseas
includ
diabet
vascular
diseas
chronic
renal
diseas
recent
possibl
role
ra
pathogenesi
chronic
liver
diseas
suggest
find
mark
upregul
intrahepat
ra
compon
experiment
liver
injuri
blockad
ra
improv
experiment
hepat
fibrosi
identif
angiotensin
convert
enzym
homologu
ace
highlight
ra
complex
previous
thought
fig
catalys
convers
angiotensin
ang
ii
ang
lesser
extent
ang
ang
convert
ang
ace
ang
number
import
action
oppos
ang
ii
includ
vasodilat
inhibit
cell
prolifer
tissu
fibrosi
effect
appear
mediat
ang
receptor
ma
ang
convert
inact
peptid
fragment
ang
action
ace
use
ace
inhibitor
shown
increas
ang
level
tissu
plasma
role
peptid
product
liver
diseas
unknown
recent
report
hepat
express
increas
cirrhot
human
liver
rat
model
establish
hepat
fibrosi
suggest
enzym
could
modul
hepat
system
angiotensin
peptid
product
magnitud
signific
possibl
effect
like
depend
rel
level
ace
express
activ
differ
tissu
although
circul
ang
ii
level
elev
advanc
liver
diseas
express
ace
liver
tissu
develop
liver
diseas
effect
ang
ii
ang
level
previous
studi
therefor
use
bile
duct
ligat
bdl
model
examin
effect
chronic
liver
injuri
express
key
mediat
ra
time
cours
studi
perform
examin
sequenti
chang
occur
liver
circul
major
site
ra
express
activ
situ
perfus
rat
liver
experi
also
perform
determin
whether
fibrot
liver
increas
capac
produc
ang
ang
ii
whether
could
alter
modifi
degrad
ang
ace
inhibitor
lisinopril
effect
ang
ang
ii
portal
resist
also
studi
experiment
procedur
approv
anim
welfar
ethic
committe
austin
health
perform
accord
nhmrc
australia
guidelin
anim
experiment
principl
helsinki
declar
eightweekold
male
spraguedawley
rat
g
hous
h
lightdark
fed
standard
rat
chow
norco
lismor
nsw
australia
water
ad
libitum
week
acclimat
bdl
sham
oper
perform
rat
previous
describ
anaesthesia
achiev
intraperiton
administr
pentobarbit
mg
g
bodi
weight
boehring
ingelheim
artarmon
nsw
australia
surgeri
bdl
n
sham
n
rat
sacrif
week
n
time
point
lethal
anaesthesia
induc
intraperiton
inject
pentobarbit
boehring
ingelheim
australia
cardiac
blood
taken
tube
contain
either
heparin
endopeptidas
inhibitor
mix
see
liver
tissu
sampl
snap
frozen
liquid
nitrogen
store
use
gene
express
autoradiographi
hydroxyprolin
quantif
liver
tissu
fix
paraformaldehyd
paraffin
embed
histolog
assess
addit
tissu
sampl
kidney
lung
small
intestin
week
taken
ace
activ
assay
group
rat
underw
situ
perfus
liver
studi
week
bdl
n
agematch
healthi
rat
serv
control
n
use
standard
techniqu
liver
perfus
oxygen
krebshenseleit
solut
bovin
serum
albumin
bsa
dextros
portal
flow
kept
constant
ml
per
minut
nonrecircul
system
ang
ii
administ
pmol
bolu
inject
sampl
effluent
collect
continu
separ
tube
everi
subdiaphragmat
ivc
two
control
sampl
taken
prior
ang
ii
inject
experi
repeat
ident
fashion
follow
preincub
ace
inhibitor
lisinopril
moll
sampl
effluent
analys
ang
use
radioimmunoassay
investig
intrahepat
vasoact
respons
ang
situ
perfus
liver
bdl
rat
week
surgeri
n
agematch
control
rat
n
given
vari
bolu
dose
ang
procedur
repeat
anoth
group
control
liver
n
preconstrict
phenylephrin
chang
portal
pressur
measur
use
open
vertic
column
attach
portal
vein
vasoconstrict
respons
ang
ii
also
compar
control
n
week
post
bdl
liver
n
viabil
prepar
determin
macroscop
histolog
appear
liver
togeth
oxygen
consumpt
substrat
ang
via
ang
ii
catalys
angiotensin
convert
enzym
ace
degrad
ace
inact
peptid
ang
receptor
ang
ii
type
receptor
ml
blood
effluent
endopeptidas
inhibitor
mix
mmol
na
edta
mol
nethylmaleimid
tiuml
aprotinin
measur
angiotensin
peptid
level
plasma
bilirubin
alanin
aminotransaminas
alt
alkalin
phosphatas
alp
gammaglutamyl
transpeptidas
ggt
measur
autoanalys
beckman
instrument
fullerton
ca
us
collagen
content
liver
determin
measur
liver
hydroxyprolin
colorimetr
assay
previous
describ
qpcr
carri
use
multiplex
target
gene
endogen
refer
gene
amplifi
singl
well
detail
dualfluoresc
label
oligonucleotid
probe
primer
given
tabl
probe
primer
design
use
primer
express
softwar
program
pe
appli
biosystem
ca
usa
predevelop
taqman
ribosom
rna
kit
use
endogen
refer
gene
pe
biosystem
sampl
run
analys
duplic
normal
valu
sham
tissu
use
calibr
given
valu
bdl
group
compar
calibr
frozen
liver
kidney
tissu
section
lm
four
time
point
cut
cryostat
microm
germani
thaw
mount
onto
slide
specif
radioligand
use
ace
autoradiographi
previous
describ
quantit
bind
densiti
determin
computeris
densitometri
analysi
activ
plasma
cell
membran
prepar
determin
use
quench
fluoresc
substrat
acetylalaproli
oh
mcaapk
dnp
oh
describ
previous
fluoresc
k
nm
k
em
nm
measur
use
fluorstar
optima
plate
reader
bmg
technolog
specif
activ
determin
use
millennium
inhibitor
gift
dr
natali
dale
millenium
pharmaceut
cambridg
usa
ace
substrat
hippurylhisleu
use
determin
ace
specif
activ
use
modif
standard
ace
assay
plasma
concentr
ang
ii
ang
measur
radioimmunoassay
antibodi
ang
ii
ang
rais
rabbit
guinea
pig
respect
natur
peptid
sequenc
human
conjug
bovin
thyroglobulin
intraand
interassay
coeffici
variat
ang
ii
ang
respect
mean
group
compar
use
anova
pearson
correl
coeffici
use
individu
variabl
consider
variat
observ
data
log
transform
stabil
variat
use
analys
data
present
leastsquar
mean
sem
anova
repeat
measur
perform
data
deriv
liver
perfus
experi
baselinecorrect
mean
valu
baselinecorrect
area
ang
curv
determin
p
valu
less
consid
statist
signific
statist
analys
carri
use
sa
comput
packag
sa
statist
version
cari
nc
usa
histolog
analysi
show
either
extens
fibrosi
week
sever
fibrosi
week
liver
parenchyma
follow
bdl
plasma
ggt
alt
alp
bilirubin
level
significantli
elev
bdl
rat
compar
sham
group
four
time
point
p
p
data
shown
bdl
liver
show
progress
increas
hydroxyprolin
content
week
week
surgeri
compar
sham
rat
level
reach
time
higher
week
p
data
shown
bile
duct
ligat
result
signific
chang
hepat
gene
express
week
increas
p
compar
sham
rat
fig
express
increas
week
level
higher
p
bdl
compar
sham
rat
activ
follow
similar
pattern
gene
express
higher
activ
p
bdl
sham
fig
hepat
ace
gene
express
increas
one
week
bdl
p
week
increas
compar
sham
p
fig
vitro
ace
autoradiographi
show
weak
ace
label
sham
liver
liver
bdl
rat
show
timedepend
r
p
increas
intens
distribut
label
increas
progress
week
week
p
fig
hepat
ace
activ
mirror
chang
observ
gene
express
fig
contrast
find
liver
chang
ace
activ
lung
intestin
tabl
primer
probe
sequenc
use
real
time
qpcr
analysi
probe
forward
revers
activ
kidney
week
bdl
anim
compar
sham
data
shown
similarli
ace
autoradiographi
result
show
differ
bdl
sham
kidney
week
week
surgeri
bdl
caus
chang
ma
gene
express
first
two
week
week
ma
express
increas
abruptli
p
week
greater
bdl
compar
sham
rat
p
fig
close
posit
correl
hepat
ma
gene
gene
express
r
p
bdl
rat
show
signific
increas
express
week
p
week
p
compar
sham
rat
fig
bar
repres
mean
sem
express
stain
activ
rat
rat
b
rat
c
respect
per
treatment
group
p
p
p
bdl
vs
sham
plasma
ace
activ
significantli
increas
week
bdl
anim
chang
throughout
cours
experi
sham
anim
p
vs
sham
fig
plasma
activ
low
sham
group
chang
experiment
period
parallel
hepat
express
data
bdl
rat
major
rise
plasma
activ
progress
liver
injuri
fig
strong
posit
correl
plasma
liver
activ
r
p
nonsignific
trend
plasma
ang
level
higher
bdl
group
sham
group
week
week
howev
week
bdl
rat
major
increas
p
plasma
ang
time
level
bdl
rat
significantli
p
higher
sham
fig
plasma
ang
ii
level
rose
abruptli
first
week
post
bdl
p
fell
back
level
similar
sham
week
rise
approxim
time
sham
level
week
p
fig
follow
ang
ii
bolu
inject
level
ang
produc
bdl
liver
twice
p
control
liver
fig
control
liver
follow
pretreat
ace
inhibitor
lisinopril
inject
ang
ii
produc
low
level
ang
liver
ident
pattern
observ
without
ace
inhibit
fig
howev
pretreat
bdl
liver
lisinopril
markedli
increas
ang
level
effluent
ang
level
postinject
significantli
p
higher
bdl
control
fig
led
significantli
p
elev
baselinecorrect
total
area
ang
curv
fig
portal
pressur
alter
respons
ml
dose
ang
either
control
cirrhot
liver
fig
respons
liver
vasoact
agent
confirm
end
experi
administr
bolu
dose
phenylephrin
fig
furthermor
ang
also
fail
alter
portal
pressur
situ
per
angiotensin
peptid
level
determin
radioimmunoassay
bar
repres
mean
sem
concentr
rat
per
treatment
group
p
p
p
bdl
vs
sham
situ
perfus
rat
liver
angiotensin
product
respons
angiotensin
ii
ang
ii
bolu
inject
bile
duct
ligat
bdl
rat
liver
close
circl
control
rat
liver
open
circl
liver
perfus
oxygen
kreb
henseleit
solut
bsa
min
two
outflow
effluent
sampl
collect
ang
ii
bolu
inject
pmol
given
follow
sampl
collect
liver
perfus
kreb
min
angiotensinconvert
enzym
ace
inhibitor
lisinopril
moll
throughout
sampl
collect
b
baselin
correct
total
area
angiotensin
curv
bdl
liver
fill
bar
control
liver
open
bar
without
ace
inhibitor
shown
panel
c
circlebar
repres
mean
sem
concentr
rat
per
treatment
group
p
p
p
p
baselinecorrect
bdl
vs
control
fuse
control
liver
preconstrict
phenylephrin
fig
contrast
mark
vasoconstrict
respons
ang
ii
group
cirrhot
liver
hyperrespons
ang
ii
p
compar
healthi
rat
fig
tradit
view
ra
primari
focu
vasoconstrictor
properti
ang
ii
challeng
recent
year
discoveri
suggest
play
counterregulatori
role
ace
sever
possibl
benefici
effect
peptid
product
ang
report
anim
model
hypertens
cardiac
diseas
follow
lung
injuri
caus
sar
coronaviru
infect
effect
liver
diseas
novel
ra
compon
ang
ang
receptor
ma
previous
investig
current
studi
show
rat
develop
advanc
biliari
fibrosi
increas
express
compon
classic
ra
ace
receptor
angiotensin
ii
accompani
increas
hepat
plasma
activ
increas
ma
express
liver
major
rise
plasma
level
ang
level
inde
week
post
bdl
plasma
concentr
peripher
vasodilatori
peptid
antiprolif
tissu
protect
properti
approach
vasoconstrictor
ang
ii
studi
provid
number
line
evid
suggest
diseas
liver
contribut
significantli
increas
product
ang
follow
bdl
activ
express
per
mg
tissu
increas
site
express
includ
lung
kidney
intestin
whilst
increas
liver
mass
individu
organ
taken
account
follow
bdl
liver
organ
greatest
activ
shown
previous
proteolyt
cleav
membran
metalloproteas
releas
solubl
form
catalyt
activ
thu
present
studi
diseas
liver
like
sourc
major
increas
plasma
activ
situ
perfus
rat
liver
experi
confirm
follow
administr
ang
ii
greater
amount
ang
produc
diseas
liver
control
importantli
increas
hepat
express
bdl
liver
accompani
upregul
ace
express
activ
find
ang
releas
bdl
sham
liver
greatli
increas
ace
inhibit
indic
high
level
hepat
ace
activ
facilit
breakdown
ang
reduc
ang
releas
fig
confirm
bdl
liver
much
greater
capac
metabol
exogen
administ
ang
ii
ang
much
ang
subsequ
broken
ace
find
keep
concept
net
tissu
product
ang
ang
ii
determin
rel
activ
ace
whilst
primari
purpos
studi
examin
effect
liver
injuri
novel
ma
axi
ra
also
document
first
time
progress
chang
occur
ace
ang
ii
level
fibrosi
develop
model
current
studi
demonstr
bimodel
chang
plasma
ang
ii
level
cours
experi
initi
mark
rise
week
one
follow
fall
level
week
signific
rise
week
chang
like
reflect
balanc
influenc
multipl
factor
includ
acut
respons
initi
liver
injuri
follow
bdl
surgeri
increas
hepat
serum
ace
activ
ang
ii
degrad
hepat
serum
activ
system
ra
respons
develop
portal
hypertens
vasodilat
recent
g
proteincoupl
receptor
ma
report
princip
function
receptor
ang
howev
limit
understand
factor
control
ma
express
relationship
present
studi
show
transcript
ma
gene
liver
close
link
gene
express
provid
support
concept
develop
hepat
ma
axi
liver
fibrosi
progress
increas
ma
avail
transduc
ang
signal
furthermor
ang
shown
vasodil
number
vascular
bed
thu
might
expect
reduc
intrahepat
tone
cirrhot
liver
effect
might
help
counterbal
vasoconstrict
mediat
local
gener
vasoact
hormon
endothelin
ang
ii
howev
despit
mark
upregul
ma
receptor
express
present
data
show
ang
elicit
intrahepat
vasodil
respons
perfus
bdl
rat
liver
thu
appear
whilst
breakdown
local
produc
ang
ii
may
help
protect
cirrhot
liver
ang
ii
mediat
vasoconstrict
tissu
injuri
detect
direct
effect
ang
sinusoid
resist
possibl
reflect
known
gener
impair
depend
vasodilat
cirrhot
liver
contrast
bdl
liver
hyperrespons
ang
ii
compar
healthi
rat
suggest
situ
perfus
model
appropri
measur
pressur
chang
respons
angiotensin
peptid
latter
find
also
interest
given
rel
import
ang
ii
mediat
increas
portal
resist
question
base
studi
hepat
hemodynam
isol
perfus
cirrhot
rat
liver
suggest
ang
ii
mediat
vasoconstrict
attenu
cirrhot
liver
conclus
studi
show
bdl
rat
ang
level
markedli
increas
chronic
liver
injuri
progress
suggest
like
reflect
increas
activ
liver
plasma
convers
ang
ii
ang
diseas
liver
chang
express
confin
liver
indic
repres
local
respons
liver
injuri
andor
upregul
receptor
axi
ra
find
rais
possibl
upregul
hepat
ma
gener
ang
repres
counterregulatori
respons
rasmedi
liver
injuri
whether
organ
manipul
axi
may
affect
tissu
injuri
chronic
liver
diseas
remain
determin
